喀什先天性勃起障碍喀什治妇科哪家比较好,喀什男不硬怎么办,喀什勃起困难多久能治好,喀什包茎手术后7天,喀什终止怀孕什么价格,喀什哪里治疗阳痿更专业,喀什如果验孕棒是一深一浅

BEIJING, Aug. 30 (Xinhuanet) -- The search giant Google admits it sees the new Google+ social network as an "identity service" or platform on which it can build other products, according to media reports.Google chariman Eric Schmidt said Google isn't interested in changing its policies to accommodate users such as political dissidents or others who prefer to remain anonymous: If people want to remain anonymous, then they shouldn't use Google+."Fundamentally, [Google+] depends on people using their real names if they're going to build future products that leverage that information," NPR's Andy Carvin wrote in a post on Google+ as he paraphrased Schmidt's remarks.Critics say the move is harmful to political activists, victims of harassment and numerous other groups for whom using a real name online might pose a safety risk, according to CNN reports."Regarding people who are concerned about their safety, [Schmidt] said G+ is completely optional," Carvin wrote.Meanwhile, according to Carvin, Schmidt also said "the Internet would be better if we knew you were a real person rather than a dog or a fake person. Some people are just evil and we should be able to ID them and rank them downward."

TAIYUAN, June 18 (Xinhua) -- A Chinese medical university will join hands with the Massey University of New Zealand to set up a community clinic specializing in chronic diseases in north China's Shanxi Province.The community clinic in Taiyuan, the provincial capital city, will provide medical services to more than 7,500 residents in the city's Hanxiguandong community, Ma Qianjin, vice president of the Shanxi University of Traditional Chinese Medicine, said on Friday.Residents will be able to seek advice from both Chinese and New Zealand experts on how to prevent chronic diseases like diabetes, said Ma.The clinic, which is expected to open this year, will also provide residents with free health check-ups and create health records for them.Bruce Ullrich, a Massey University board member, said on Friday that the clinic will integrate Western service with traditional Chinese medical techniques in its prevention and treatment of chronic diseases."The community clinic will mainly focus on people with obesity, diabetes and other chronic diseases. The cost of disease prevention will be dramatically lower than the cost of treatment," said Ullrich.Zhang Xinwei, deputy director of the provincial science and technology bureau, said that if the clinic's practices are successful, the model may be adopted by other regions in China.

UNITED NATIONS, June 9 (Xinhua) -- Partners from UN agencies and governments, as well as civil society and the private sector gathered here Thursday to launch "Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive.""Governments and foundations that support this plan are saying: we treasure all life equally," said UN Secretary-General Ban Ki- moon, who spoke at the event. "We give all people the best possible chance. We provide health care to all who need it."This new plan, which was formulated by a Global Task Team of more than 30 governments and 50 international and national organizations, aims to bring the number of new HIV infections in children to zero by the middle of the decade and help their mothers survive.The launch of Countdown to Zero came on the sidelines of the UN High-Level Meeting on AIDS, which runs from June 8-10, and has been an opportunity for participants to take stock of gains made in combating the disease and to agree on a declaration that will direct the actions of member states to prevent and treat HIV/AIDS over the next five years.Ban told the audience at the launch that history has proven that it is possible to make great strides in fighting HIV/AIDS, with the right amount of effort and coordination."Let us not forget that some regions have nearly achieved no new infections from mother to child," he said. "If we push hard, as we have committed today, with your continued help and with the will to do what is right for the world, we can spread this success to mothers everywhere."According to the Joint UN Program on HIV/AIDS (UNAIDS), the rate of HIV/AIDS transmission from mother to child was been reduced by 26 percent from 2001 to 2009.Former U.S. President Bill Clinton, who spoke at the launch, said that he believes the time to eliminate HIV/AIDS in children is at hand."We are here because we all recognize that the time has finally come to end pediatric AIDS worldwide and we believe we can do it," he said. "We know we have the capacity to produce the medicine, we know that."Clinton emphasized the fact that HIV/AIDS is often prevalent in less developed countries. Sub-Saharan Africa remains the region that has the most HIV/AIDS infected people."There are still too many kids who are born HIV-positive," he said. "Just 22 countries account for 90 percent of those pediatric infections."He said that there are not only moral reasons for wealthier countries to help these nations by investing in their HIV/AIDS responses, but that by doing so they increase their soft power -- influence that utilizes non-coercive measures."I think its important in a world where no one wants to look weak and the military justifiably has a claim on all of our budgets, we not forget that what my secretary-of-state often refers to as soft power issues, they have a bigger impact on our long term security," Clinton said. "I think that accounts in no small measure for the presence of leaders of global corporations here at this meeting today, they know this as well."Collaboration and close coordination of responses to HIV/AIDS, Clinton said, is also essential."There are still too many places where HIV and maternal and child health groups work completely separately," he said. "That dramatically reduces the likelihood that mothers are their babies will receive the full range of care. We simply have to all work together, both within governments and all of those who are trying to help to ensure that mothers get the drugs they should and that their babies are born without the virus."Clinton said that Goodluck Jonathan, president of Nigeria, who gave a statement at the launch as well, is an excellent example of the "strong political leadership and personal commitment" necessary to defeat HIV/AIDS and reach to goals set by the Countdown to Zero plan.In his speech, Jonathan said that Africa is has banded together through the Abuja Declaration, adopted in 2001, which turned attention and resources towards public health problems on the continent, particularly HIV/AIDS."That declaration was to make African countries spend at least 15 percent of their budget on their health sector and a reasonable percentage of this would be geared towards HIV prevention and control," he said.Budgeting shortfalls for fighting HIV/AIDS in Africa must be accounted for, Jonathan said, as African countries must not rely solely on donors to fund their responses."I intend to explore in the coming months in collaboration with colleagues in sub-Saharan Africa an effective and creative funding mechanism to ensure ownership and long terms sustainability of the HIV and AIDS response in Africa," he said.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, June 15 (Xinhua) -- Facebook has hired Joe Lockhart, who was former U.S. President Bill Clinton's press secretary during the last two years of his second term, as the social network company's vice president of global communications, U.S. media reported on Wednesday.Lockhart, 51, will report to Elliot Schrage, Facebook's current vice president of global communications, marketing and public policy, The Wall Street Journal said in a report."His experience building and running a press office at the White House gives him particular appreciation for the demands of a global 24-hour news cycle and the challenges of responding effectively to intense scrutiny," Schrage said of Lockhart's arrival.Lockhart will start at Facebook on July 15 and will move from Washington D.C. to Facebook's headquarters in California.Lockhart is the latest Washington insider to join Facebook as the world's largest social networking site is facing intense scrutiny for its privacy practices and growing global presence, The Wall Street Journal pointed out.Last year, Facebook also hired White House economic adviser Marne Levine to serve as its vice president of global public policy.More recently, Facebook hired former Bush administration officials Joel Kaplan as its vice president for U.S. public policy, and Myriah Jordan, who will become a policy manager focusing on congressional relations.